TABLE 2.
Characteristics of the case and control patients in the nationwide cohort
| Dementia cases (N = 4849) | Controls (N = 48,506) | |
|---|---|---|
| Male sex, n (%) | 2299 (47.4) | 22,998 (47.4) |
| Age, n (%) | ||
| < 70 years | 1278 (26.4) | 12,784 (26.4) |
| 70–80 years | 2268 (46.8) | 22,688 (46.8) |
| 80–90 years | 1260 (26.0) | 12,612 (26.0) |
| > 90 years | 43 (0.9) | 422 (0.9) |
| Diabetes duration, median (IQR) a , b | 6.0 (3.0–10.0) | 6.0 (3.0–9.0) |
| GLP‐1 RAs, n (%) | ||
| 0 years | 4575 (94.3) | 44,594 (91.9) |
| 1–2 years | 59 (1.2) | 623 (1.3) |
| 2–3 years | 35 (0.7) | 586 (1.2) |
| 3–4 years | 35 (0.7) | 483 (1.0) |
| 4–5 years | 74 (1.5) | 1076 (2.2) |
| Stroke, n (%) b | 760 (15.7) | 5628 (11.6) |
| Myocardial infarction, n (%) b | 527 (10.9) | 5241 (10.8) |
| Hypertension, n (%) b | 3252 (67.1) | 31,961 (65.9) |
| Chronic renal disease, n (%) b | 233 (4.8) | 2287 (4.7) |
| Educational attainment, n (%) b , c | ||
| Basic | 2490 (51.4) | 23,920 (49.3) |
| Medium | 1508 (31.1) | 14,971 (30.9) |
| Advanced | 427 (8.8) | 4681 (9.7) |
a
Years since initiation of second‐line diabetes treatment.
b
At beginning of 5‐year exposure window.
c
Educational status unknown in 424 (8.7%) cases and in 4934 (10.2%) controls.
Abbreviations: GLP‐1 RA, glucagon‐like peptide‐1 receptor agonist; IQR, interquartile range.